{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:22:00Z","timestamp":1792552920952,"version":"4.5.0"},"reference-count":84,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA168505"],"award-info":[{"award-number":["CA168505"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA227847"],"award-info":[{"award-number":["CA227847"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA224065"],"award-info":[{"award-number":["CA224065"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>BRAF-activating mutations are the most frequent driver mutations in papillary thyroid cancer (PTC). Targeted inhibitors such as dabrafenib have been used in advanced BRAF-mutated PTC; however, acquired resistance to the drug is common and little is known about other effectors that may play integral roles in this resistance. In addition, the induction of PTC dedifferentiation into highly aggressive KRAS-driven anaplastic thyroid cancer (ATC) has been reported. We detected a novel RAC1 (P34R) mutation acquired during dabrafenib treatment in a progressive metastatic lesion with ATC phenotype. To identify a potential functional link between this novel mutation and tumor dedifferentiation, we developed a cell line derived from the metastatic lesion and compared its behavior to isogenic cell lines and primary tumor samples. Our data demonstrated that RAC1 mutations induce changes in cell morphology, reorganization of F-actin almost exclusively at the cell cortex, and changes in cell adhesion properties. We also established that RAC1 amplification, with or without mutation, is sufficient to drive cell proliferation and resistance to BRAF inhibition. Further, we identified polyploidy of chromosome 7, which harbors RAC1, in both the metastatic lesion and its derived cell line. Copy number amplification and overexpression of other genes located on this chromosome, such as TWIST1, EGFR, and MET were also detected, which might also lead to dabrafenib resistance. Our study suggests that polyploidy leading to increased expression of specific genes, particularly those located on chromosome 7, should be considered when analyzing aggressive thyroid tumor samples and in further treatments.<\/jats:p>","DOI":"10.3390\/cancers13194950","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T10:55:40Z","timestamp":1633085740000},"page":"4950","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient"],"prefix":"10.3390","volume":"13","author":[{"given":"Rozita","family":"Bagheri-Yarmand","sequence":"first","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naifa L.","family":"Busaidy","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5577-2230","authenticated-orcid":false,"given":"Elena","family":"McBeath","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-6337","authenticated-orcid":false,"given":"Brian P.","family":"Danysh","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt W.","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Moss","sequence":"additional","affiliation":[{"name":"Bioinformatics & Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argun","family":"Akcakanat","sequence":"additional","affiliation":[{"name":"Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick K. S.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Knippler","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"},{"name":"Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalyn A.","family":"Golden","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle D.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha S.","family":"Multani","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenna R.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha H.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-3266","authenticated-orcid":false,"given":"Matthew D.","family":"Ringel","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"},{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4899-8039","authenticated-orcid":false,"given":"Marie Claude","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"3","article-title":"Thyroid carcinoma: Epidemiology, histology, and diagnosis","volume":"13","author":"Shah","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1210\/JC.2015-1346","article-title":"Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987\u20132012","volume":"100","author":"Carhill","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.biopha.2008.07.056","article-title":"Dedifferentiated thyroid cancer: A therapeutic challenge","volume":"62","author":"Antonelli","year":"2008","journal-title":"Biomed. Pharm."},{"key":"ref_5","unstructured":"(2014). The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 159, 676\u2013690."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12672-014-0207-9","article-title":"BRAF inhibitors: Experience in thyroid cancer and general review of toxicity","volume":"6","author":"Cabanillas","year":"2015","journal-title":"Horm. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: The first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2013.794220","article-title":"Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies","volume":"9","author":"Gibney","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1159\/000504291","article-title":"Response to BRAF\/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma","volume":"12","author":"Bjursten","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Trudel, S., Odolczyk, N., Dremaux, J., Toffin, J., Regnier, A., Sevestre, H., Zielenkiewicz, P., Arnault, J.P., and Gubler, B. (2014). The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-727"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1200\/JCO.2017.35.15_suppl.6022","article-title":"Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated paillary thyroid carcinoma","volume":"35","author":"Shah","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.18632\/oncotarget.9023","article-title":"Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model","volume":"7","author":"Danysh","year":"2016","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.6004\/jnccn.2019.7292","article-title":"KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer","volume":"17","author":"Owen","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/thy.2019.0514","article-title":"Acquired Secondary RAS Mutation in BRAF(V600E)-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors","volume":"30","author":"Cabanillas","year":"2020","journal-title":"Thyroid"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1478-811X-8-23","article-title":"Rac and Rho GTPases in cancer cell motility control","volume":"8","author":"Parri","year":"2010","journal-title":"Cell Commun. Signal"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","article-title":"The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF","volume":"74","author":"Watson","year":"2014","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1073\/pnas.1216141110","article-title":"Transforming mutations of RAC guanosine triphosphatases in human cancers","volume":"110","author":"Kawazu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1016\/j.yexcr.2007.08.017","article-title":"Rac1 activity regulates proliferation of aggressive metastatic melanoma","volume":"313","author":"Bauer","year":"2007","journal-title":"Exp. Cell Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1073\/pnas.1220895110","article-title":"RAC1P29S is a spontaneously activating cancer-associated GTPase","volume":"110","author":"Davis","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4149\/neo_2018_180115N31","article-title":"Detection of driver mutations in FFPE samples from patients with verified malignant melanoma","volume":"66","author":"Malicherova","year":"2019","journal-title":"Neoplasma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ccell.2019.05.015","article-title":"RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance","volume":"36","author":"Lionarons","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2018.01.021","article-title":"Systematic Functional Annotation of Somatic Mutations in Cancer","volume":"33","author":"Ng","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.7618083","article-title":"Regulation of human leukocyte p21-activated kinases through G protein--coupled receptors","volume":"269","author":"Knaus","year":"1995","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"36238","DOI":"10.1074\/jbc.M002138200","article-title":"Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells","volume":"275","author":"Vadlamudi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1677\/ERC-10-0168","article-title":"Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion","volume":"17","author":"McCarty","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1530\/ERC-14-0424","article-title":"BRAF activates and physically interacts with PAK to regulate cell motility","volume":"21","author":"McCarty","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/ERC-19-0188","article-title":"MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition","volume":"26","author":"Knippler","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.str.2005.03.007","article-title":"The active conformation of the PAK1 kinase domain","volume":"13","author":"Lei","year":"2005","journal-title":"Structure"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"32565","DOI":"10.1074\/jbc.274.46.32565","article-title":"Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity","volume":"274","author":"Zenke","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0960-9822(97)70091-5","article-title":"Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells","volume":"7","author":"Sells","year":"1997","journal-title":"Curr. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"R762","DOI":"10.1016\/j.cub.2009.06.053","article-title":"The shape of motile cells","volume":"19","author":"Mogilner","year":"2009","journal-title":"Curr. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.7150\/jca.24824","article-title":"Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis","volume":"9","author":"Lou","year":"2018","journal-title":"J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.neo.2018.09.003","article-title":"The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells","volume":"20","author":"Puli","year":"2018","journal-title":"Neoplasia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.18632\/oncotarget.3268","article-title":"Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.18632\/oncotarget.26798","article-title":"MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer","volume":"10","author":"Garcia","year":"2019","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-17-1124","article-title":"BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors","volume":"17","author":"Stagni","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/CMR.0000000000000398","article-title":"Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E","volume":"27","author":"Hallmeyer","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Dominguez","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28087","DOI":"10.1074\/jbc.M112.377218","article-title":"Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)\/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma","volume":"287","author":"Yadav","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.18632\/oncotarget.13480","article-title":"Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation","volume":"8","author":"Byeon","year":"2017","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"42445","DOI":"10.18632\/oncotarget.6442","article-title":"Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model","volume":"6","author":"Duquette","year":"2015","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/374457a0","article-title":"An essential role for Rac in Ras transformation","volume":"374","author":"Qiu","year":"1995","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1158\/0008-5472.CAN-07-2300","article-title":"Requirement for Rac1 in a K-ras induced lung cancer in the mouse","volume":"67","author":"Kissil","year":"2007","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.gastro.2011.04.043","article-title":"Early requirement of Rac1 in a mouse model of pancreatic cancer","volume":"141","author":"Heid","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1038\/onc.2010.95","article-title":"Rac1 is crucial for Ras-dependent skin tumor formation by controlling Pak1-Mek-Erk hyperactivation and hyperproliferation in vivo","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/onc.2017.400","article-title":"Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors","volume":"37","author":"Feng","year":"2018","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.bbrc.2009.06.125","article-title":"Overexpression of Rac1 in leukemia patients and its role in leukemia cell migration and growth","volume":"386","author":"Wang","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.7150\/jca.16198","article-title":"Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer","volume":"7","author":"Zhou","year":"2016","journal-title":"J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3892\/ijo.2015.2836","article-title":"Rac1 is correlated with aggressiveness and a potential therapeutic target for gastric cancer","volume":"46","author":"Ji","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-0436-03","article-title":"Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer","volume":"10","author":"Kamai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1038\/sj.onc.1203621","article-title":"Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, Rac1b","volume":"19","author":"Schnelzer","year":"2000","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2018.208843","article-title":"FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways","volume":"104","author":"Wu","year":"2019","journal-title":"Haematologica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1038\/bjc.2014.221","article-title":"Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC)","volume":"110","author":"Skvortsov","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1038\/sj.onc.1203233","article-title":"Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors","volume":"18","author":"Jordan","year":"1999","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1535-7163.MCT-18-0955","article-title":"RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer","volume":"18","author":"Goka","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1038\/sj.onc.1208182","article-title":"Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation","volume":"23","author":"Singh","year":"2004","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Faria, M., Matos, P., Pereira, T., Cabrera, R., Cardoso, B.A., Bugalho, M.J., and Silva, A.L. (2017). RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0172689"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1530\/EJE-12-0960","article-title":"RAC1b overexpression in papillary thyroid carcinoma: A role to unravel","volume":"168","author":"Silva","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"021005","DOI":"10.1115\/1.4035121","article-title":"The Mechanics of Single Cell and Collective Migration of Tumor Cells","volume":"139","author":"Lintz","year":"2017","journal-title":"J. Biomech. Eng."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.trecan.2020.08.008","article-title":"Aneuploidy in Cancer: Lessons from Acute Lymphoblastic Leukemia","volume":"7","author":"Molina","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cell.2018.02.037","article-title":"Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns","volume":"173","author":"Sack","year":"2018","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1155\/1998\/275452","article-title":"Genetic heterogeneity of benign thyroid lesions. Static and flow cytometry, karyotyping and in situ hybridization analysis","volume":"16","author":"Cigudosa","year":"1998","journal-title":"Anal. Cell Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0165-4608(97)00057-5","article-title":"Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology","volume":"101","author":"Belge","year":"1998","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_70","first-page":"369","article-title":"Significance of trisomy 7 and 12 in thyroid lesions with follicular differentiation: A cytogenetic and in situ hybridization study","volume":"79","author":"Roque","year":"1999","journal-title":"Lab. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0165-4608(99)00143-0","article-title":"Detection of numerical chromosome anomalies in interphase cells of benign and malignant thyroid lesions using fluorescence in situ hybridization","volume":"117","author":"Barril","year":"2000","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-4608(90)90184-C","article-title":"Chromosomal changes in thyroid tumors. Relation with DNA content, karyotypic features, and clinical data","volume":"50","author":"Teyssier","year":"1990","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0165-4608(92)90253-5","article-title":"Significance of trisomy 7 in thyroid tumors","volume":"62","author":"Herrmann","year":"1992","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/gcc.2870090306","article-title":"Numerical chromosomal aberrations in thyroid tumors detected by double fluorescence in situ hybridization","volume":"9","author":"Taruscio","year":"1994","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/gcc.2870130304","article-title":"Cytogenetic findings in 31 papillary thyroid carcinomas","volume":"13","author":"Roque","year":"1995","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/gcc.10238","article-title":"Aneuploidy in oncocytic lesions of the thyroid gland: Diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations","volume":"38","author":"Dettori","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.neo.2019.02.003","article-title":"Single Chromosome Aneuploidy Induces Genome-Wide Perturbation of Nuclear Organization and Gene Expression","volume":"21","author":"Braun","year":"2019","journal-title":"Neoplasia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","article-title":"Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers","volume":"52","author":"Kim","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-020-03064-z","article-title":"Chromothripsis drives the evolution of gene amplification in cancer","volume":"591","author":"Shoshani","year":"2021","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.ajpath.2013.08.009","article-title":"Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells","volume":"183","author":"Suprynowicz","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1210\/jc.2008-1102","article-title":"Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification","volume":"93","author":"Schweppe","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","article-title":"Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies","volume":"25","author":"Landa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_84","first-page":"2889","article-title":"All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1","volume":"85","author":"Kurebayashi","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4950\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:08:18Z","timestamp":1760166498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":84,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194950"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194950","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}